Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Petty

Showing results (171-180 of 174) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 174 results.
Journal of Clinical Pharmacology|December 19, 2003
Pharmacokinetics of etoricoxib in patients with renal impairmentNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cell Death & Disease|September 25, 2023
Identification of a miRNA multi-targeting therapeutic strategy in glioblastomaArthur Bassot, Helena Dragic, Sarah Al Haddad, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 26, 2009
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonistJohn R Atack, Karen A Maubach, Keith A Wafford, et al.
Pageof 18

Showing results (171-180 of 174) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 174 results.
Journal of Clinical Pharmacology|December 19, 2003
Pharmacokinetics of etoricoxib in patients with renal impairmentNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cell Death & Disease|September 25, 2023
Identification of a miRNA multi-targeting therapeutic strategy in glioblastomaArthur Bassot, Helena Dragic, Sarah Al Haddad, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 26, 2009
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonistJohn R Atack, Karen A Maubach, Keith A Wafford, et al.
Pageof 18